Tested Applications
| Positive FC (Intra) detected in | MCF-7 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.80 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| IF | See 1 publications below |
Product Information
CL488-68235 targets KIAA1429 in IF, FC (Intra) applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | KIAA1429 fusion protein Ag22449 Predict reactive species |
| Full Name | KIAA1429 |
| Calculated Molecular Weight | 1812 aa, 202 kDa |
| Observed Molecular Weight | 200-210 kDa |
| GenBank Accession Number | BC113380 |
| Gene Symbol | KIAA1429 |
| Gene ID (NCBI) | 25962 |
| RRID | AB_3084451 |
| Conjugate | CoraLite® Plus 488 Fluorescent Dye |
| Excitation/Emission Maxima Wavelengths | 493 nm / 522 nm |
| Form | Liquid |
| Purification Method | Protein G purification |
| UNIPROT ID | Q69YN4 |
| Storage Buffer | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
VIRMA (KIAA1429) is a key component of m6A methyltransferase (writer) complex that include METTL3, METTL14, WTAP, VIRMA, HAKAI, ZC3H13, and RBM15. VIRMA mediates methylation in the 3'UTR and around the stop codon, thus affecting alternative polyadenylation. VIRMA has been reported to act as an oncogenic factor in breast cancer and liver cancer. KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples, and high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. BRAF-mediated phosphorylation of KIAA1429 facilitates its aggregation in the cytoplasm. Furthermore, cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance (PMID: 40611274).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CL Plus 488 KIAA1429 antibody CL488-68235 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
